RT @SABOURETCardio
#CAC Scoring for Risk Assessment in pts with severe #dyslipidemia : need to update the #Guidelines ? https://www.ajconline.org/article/S0002-9149(22)01183-3/fulltext

#CardioMastodon Lipoprotein #metabolism in #Dyslipidemia & the Roles of APOC3 & ANGPTL3 in Clinical Development of APOC3 Inhibitors .+ve relationship between increased levels of circulating triglycerides & #CVD has been observed for decades. Driven by genetic cohort studies, inhibitors of APOC3 &ANGPTL that reduce circulating triglycerides are poised to enter clinical practice.
https://www.ahajournals.org/doi/10.1161/ATVBAHA.122.317966

Risks and burdens of incident dyslipidaemia in long COVID: a cohort study - The Lancet Diabetes & Endocrinology

A new study on #Dyslipidemia and #Covid19, especially #LongCovid

https://www.thelancet.com/journals/landia/article/PIIS2213-8587(22)00355-2/fulltext

I am pleased to announce 🤩 🤓 that our paper led by prof. Jolanta Małyszko has been published in Expert Opinion on Therapeutic Targets. 👌

📑 Kidney and lipids: novel potential therapeutic targets for dyslipidemia in kidney disease?

✳️ https://doi.org/10.1080/14728222.2022.2161887 ✳️

#nephrology #kidneydisease #lipids #dyslipidemia #therapeutics